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Abstract Quality of survival of childhood-onset cranio-
pharyngioma patients is frequently impaired by hypotha-
lamic involvement or surgical lesions sequelae such as
obesity and neuropsychological deﬁcits. Oxytocin, a pep-
tide hormone produced in the hypothalamus and secreted
by posterior pituitary gland, plays a major role in regula-
tion of behavior and body composition. In a cross-
sectional study, oxytocin saliva concentrations were ana-
lyzed in 34 long-term craniopharyngioma survivors with
and without hypothalamic involvement or treatment-
related damage, recruited in the German Childhood Cra-
niopharyngioma Registry, and in 73 healthy controls,
attending the Craniopharyngioma Support Group Meeting
2014. Oxytocin was measured in saliva of craniophar-
yngioma patients and controls before and after standar-
dized breakfast and associations with gender, body mass
index, hypothalamic involvement, diabetes insipidus, and
irradiation were analyzed. Patients with preoperative
hypothalamic involvement showed similar oxytocin levels
compared to patients without hypothalamic involvement
and controls. However, patients with surgical hypotha-
lamic lesions grade 1 (anterior hypothalamic area) pre-
sented with lower levels (p = 0.017) of oxytocin under
fasting condition compared to patients with surgical lesion
of posterior hypothalamic areas (grade 2) and patients
without hypothalamic lesions (grade 0). Craniophar-
yngioma patients’ changes in oxytocin levels before and
after breakfast correlated (p = 0.02) with their body mass
index. Craniopharyngioma patients continue to secrete
oxytocin, especially when anterior hypothalamic areas are
not involved or damaged, but oxytocin shows less varia-
tion due to nutrition. Oxytocin supplementation should be
explored as a therapeutic option in craniopharyngioma
patients with hypothalamic obesity and/or behavioral
pathologies due to lesions of speciﬁc anterior hypotha-
lamic areas. Clinical trial number: KRANIOPHAR-
YNGEOM 2000/2007(NCT00258453; NCT01272622).
Keywords Craniopharyngioma ● Hypothalamus ● Obesity ●
Oxytocin ● Behavior
Introduction
Childhood-onset craniopharyngioma (CP) are rare intra-
cranial embryonal malformations of the sellar region arising
from remnants of Rathke’s pouch [1]. CP show low-grade
histological malignancy (WHO °I) and frequently effect
hypothalamic and pituitary regions due to their location [2].
This hypothalamic involvement (HI) of CP and/or
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treatment-related lesions of this region usually result in
endocrine deﬁciencies, neuropsychological deﬁcits, patho-
logical patterns of eating behavior, and obesity with major
negative impact on prognosis and quality of life in surviving
patients [3–7]. Substitution therapy for endocrine deﬁ-
ciencies—hydrocortisone, sex steroids, growth hormone,
vasopressin, and thyroid hormones—is an elemental part in
CP treatment for patients with disturbances involving the
hypothalamic and pituitary regions [2].
The peptide hormone oxytocin, which is primarily syn-
thesized in the paraventricular and supraoptic nuclei of the
hypothalamus and released by the posterior pituitary, has
not been analyzed in the context of CP before this study [8].
It can be assumed that oxytocin synthesis and release is
disturbed in patients with CP, similar to the other hormones
of the pituitary gland. Oxytocin is similar to the peptide
hormone vasopressin, as its structure differs only by two
amino acids [9]. However, in contrast to vasopressin, whose
function is well understood and the clinical symptoms in
vasopressin-deﬁcient patients are well known [10], little is
known about the role of oxytocin in CP patients. Oxytocin
is involved in metabolism [11] and in the regulation of a
wide variety of social and non-social behaviors such as non-
social memory, anxiety, depression, and stress [12–16].
To evaluate the role of oxytocin in CP patients, we
conducted a pilot cross-sectional study analyzing a small
group of patients recruited in the German Craniophar-
yngioma Registry to assess oxytocin concentrations in sal-




This study analyzed patients with adamantinomatous
childhood-onset CP, recruited in the German Craniophar-
yngioma Registry and prospectively evaluated in the multi-
center trials HIT Endo and KRANIOPHARYNGEOM 2000/
2007 (Clinical Trial No.: NCT00258453; NCT01272622),
who attended the 17th Annual Meeting of the German
Craniopharyngioma Support Group, Bad Sassendorf, Ger-
many, 2014. Thirty-four of 40 patients (85 %) attending this
meeting agreed to participate in the study. These 34 CP
patients (19 female, 15 male) had been initially diagnosed at
a median age of 10.5 years (range: 0.02–18.0 years). The
study cohort (n= 34) showed similar characteristics in
terms of age and gender distribution, degree of surgical
resection, HI, and hypothalamic surgical lesions when
compared with the total cohort of CP patients recruited in
the German Craniopharyngioma Registry.
Oxytocin concentrations were analyzed at a median
patient age of 20 years (range 7–41 years), with a median
interval between initial CP diagnosis and this study of 11.0
years (range: 0.5–31.0 years). They were analyzed for
height, weight, and body mass index (BMI), as well as
oxytocin concentrations in saliva, for which samples were
taken shortly before and 60 min after breakfast. For the
oxytocin concentration comparisons, a standardized and
comparable breakfast for all participants was ensured
(approx. 10–15 kcal/kg body weight; 8 a.m.). The study was
conducted during the 17thAnnual Meeting of the German
Craniopharyngioma Support Group, Bad Sassendorf,
Germany, 2014. A total of 73 healthy children, adolescents,
and adults, also attending the 17th Annual Craniophar-
yngioma Support Group Meeting, 2014, served as controls.
Body composition and the degree of obesity were eval-
uated by calculating the BMI standard deviation score
(SDS) according to the references of Rolland-Cachera et al.
[17]. The histological diagnosis of anadamantinomatous CP
was conﬁrmed by reference assessment in all cases. HI of
CP was assessed by magnetic resonance imaging (MRI),
computed tomography, and/or microscopic inspection dur-
ing surgery. Preoperative HI was deﬁned as involvement of
hypothalamic structures either by tumor growth into the
hypothalamus or displacement of hypothalamic structures
by the tumor. Surgical hypothalamic lesions were assessed
on postoperative MRI and reference-conﬁrmed by a neu-
roradiologist blinded for the clinical data based on a pre-
viously published grading system [18, 19].
The study was approved by the local standing committee
on ethical practice and written parental and/or patient con-
sent was obtained in all cases.
Oxytocin analysis in saliva
We compared saliva levels of the 34 CP patients with the
saliva of a healthy control group consisting of 41 female
and 32 male participants with a median age of 39 years
(range 8–63 years). Oxytocin saliva levels were measured
under fasting conditions as well as directly after a standar-
dized breakfast meal. In addition, we quantiﬁed changes in
oxytocin levels before and after breakfast (Δ oxytocin is
deﬁned as the difference in oxytocin after breakfast−oxy-
tocin before breakfast). To measure oxytocin saliva levels,
saliva was collected from each participant (patients and
controls) before and after breakfast using a standardized
method for saliva sampling. A white cylindrical swab was
chewed gently for 15 min by each participant and then
returned with the absorbed saliva into a salivette—a saliva
collection device. All salivettes were placed immediately on
ice and kept cool till centrifugation. After centrifugation,
patient saliva samples were stored frozen until analysis.
Oxytocin concentrations in saliva were measured by
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immunoassay [20]. Brieﬂy, a competition between bioti-
nylated oxytocin used as tracer and synthetic oxytocin
provides a displacement curve after incubation with
streptavidin-horseradish peroxidase and revelation with
TMB 3,3’,5,5’-Tetramethylbenzidine. Filtration on Amicon
Ultracel-2, membrane of 3 kDa (cutoff 3000)—both from
Merck Millipore—was performed in order to reduce inter-
ferences. Filtration recovery was measured as 68.4± 14.4 %
(coefﬁcient of variance: 21 %) of 10 pg added to hormone-
free plasma. Combined intra-assays standard deviations
(SD) for the enzyme immunoassay (EIA) (n= 10 in dupli-
cates and triplicates) were 1.05 % at 7.2 pg/ml,
1.94 % at 20 pg/ml, and 1.58 % at 200 pg/ml. Detection
limit (±2 SD from zero) was typically 0.5 pg/ml and always
under 1 pg/ml.
Statistical analyses
Statistical analysis was performed with SPSS 23® for
Windows (IBM Corporation, Somers, NY, USA) and R
version 3.1.0. For metrical variables, the comparison of two
and three independent groups was performed with the
Mann–Whitney U test and the Kruskal–Wallis test,
respectively. Post-hoc pairwise comparisons were per-
formed using Dunn’s test. For comparison of groups con-
cerning categorical variables, Fisher’s exact test was used.
Correlation was calculated with the Pearson correlation
coefﬁcient. The local signiﬁcance level was set to 0.05.
Nevertheless, all inferential statistics were intended to be
exploratory (hypotheses generating), not conﬁrmatory, and
were interpreted accordingly. Therefore, no adjustment for
multiple testing was applied.
Results
Oxytocin levels in saliva of 34 CP patients were analyzed.
Proven initial HI was detected in 20 of the 34 cases (59 %)
before ﬁrst surgical treatment of CP. Complete surgical
resection was achieved at initial diagnosis in 10 of 28 CP
patients (36 %), resection data being available for only these
28 patients. A total 14 of the 34 CP patients (41 %) received
irradiation. Based on desmopressin medication, 28 of 34 CP
patients (82 %) had presented with diabetes insipidus by the
time this study was initiated. Gender related differences in
terms of HI, degree of resection, irradiation and diabetes
insipidus were not detectable.
We compared oxytocin saliva levels in CP patients with
concentrations in saliva of healthy controls. Oxytocin saliva
levels were measured under fasting conditions as well as
directly after a standardized breakfast meal. In addition, we
quantiﬁed changes in oxytocin levels before and after
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oxytocin levels were detected in the CP patients compared
to the controls, indicating that CP patients were still able to
produce and secrete the hormone oxytocin (Table 1). In
addition, the subgroup of 20 patients with proven initial HI
did not show any signiﬁcant differences compared to
patients without initial HI and the controls (Fig. 1a–c).
Grading of the post-surgical hypothalamic lesion was
possible in 27 of the 34 patients (79 %). This analysis
showed seven patients had no treatment-related hypotha-
lamic lesion; six patients showed a surgical hypothalamic
lesion grade 1, which is deﬁned as a damage of the anterior
parts of the hypothalamic region, leaving the corpora
mammillaria intact. The grading analysis further revealed
14 patients with hypothalamic lesions grade 2, which is
deﬁned as a damage of the anterior and posterior parts of the
hypothalamic region. By comparison of these subgroups,
patients with hypothalamic lesion grade 1 showed a sig-
niﬁcant lower level of oxytocin before breakfast, compared
to patients without hypothalamic lesion and compared to
patients with hypothalamic lesion grade 2 of the anterior
and posterior hypothalamus (p= 0.017). Patients with
hypothalamic lesion grade 2 did not differ in terms of
oxytocin levels before breakfast compared to patients
without hypothalamic lesion. In the oxytocin measurements
after breakfast, again the patients with hypothalamic lesion
grade 1 showed a lower oxytocin level compared to hypo-
thalamic lesion grade 2 patients, but without reaching a
signiﬁcant level. In the analysis of Δ oxytocin before and
after breakfast, no differences were detectable (Fig. 2a–c).
By comparison of changes in oxytocin saliva levels
before and after breakfast (Δ oxytocin), no signiﬁcant dif-
ferences could be measured in patients having undergone
radiotherapy (Fig. 3a) or in those with diabetes insipidus
(Fig. 3b). Due to the important role of oxytocin in females,
we compared oxytocin expression in male and female CP
patients and controls. Again, no signiﬁcant differences
could be detected (Fig. 3c).
However, in our analysis of further clinical parameters, it
turned out that changes in oxytocin levels (Δ oxytocin)
before and after breakfast correlated signiﬁcantly (p= 0.02)
with BMI in CP patients. CP patients with a high BMI
showed smaller oxytocin changes. In controls, no sig-
niﬁcant correlation between BMI SDS and Δ oxytocin
(before/after breakfast) could be detected (Fig. 4).
Discussion
The present study reports the ﬁrst analysis of oxytocin
saliva concentrations in adamantinomatous childhood-onset
CP patients. This is signiﬁcant, as oxytocin synthesis takes
place in the hypothalamus and is released mainly via the
pituitary gland, and these structures are often damaged by
CP either from tumor involvement or its surgical treatment.
Therefore, it was suspected that oxytocin synthesis and
release would be disturbed in CP patients. However, we
could not detect a lack of oxytocin in CP patients. In
addition, we detected no difference in oxytocin saliva
concentrations compared to the healthy control group. The
conservation of oxytocin synthesis in CP patients might be
explained by a residual or preserved function of hypotha-
lamic structures and/or a taking over of synthesis function
by other neuronal regions. It has been described that—in
addition to the synthesis in the paraventricular and
supraoptic nuclei of the hypothalamus—lesser amounts of
oxytocin are generated in the bed nucleus of the stria-
terminalis, medial preoptic area, and lateral amygdala,
depending on the species [21]. The release of oxytocin in
humans is known not to happen exclusively via axonal
secretion in the posterior pituitary but also from the den-
drites (opposed to the axons) for intracerebral release [22–
24]. By discrete grading and comparisons of CP patients
with grade 1 hypothalamic surgical damage (damage
exclusively to the anterior hypothalamic structures) and
grade 2 (damage of anterior and posterior hypothalamic
regions), we found that patients with grade 1 damage only
to the anterior hypothalamus had a lower oxytocin level
before breakfast compared to patients with grade 2 damage
and to patients without any hypothalamic damage. This
ﬁnding is, however, inconclusive, because only six patients
were categorized with grade 1 hypothalamic damage.
Nevertheless, our comparison of results still lead us to
speculate that in some patients, oxytocin production and
release is diminished by hypothalamic damage due to sur-
gical treatment. The localization of the paraventricular and
supraoptic nuclei of the hypothalamus might be the reason
for preservation of oxytocin production since both nuclei
are localized in the anterior superior part of the hypothala-
mus. Growth of CP, however, typically takes place from an
anterior inferior to an upwards posterior direction. Thus, in
patients with HI, the anterior inferior (tuberal region) of the
hypothalamus is attacked ﬁrst [25]. Depending on the
direction of growth and tumor size, the paraventricular and
supraoptic nuclei may frequently be spared, resulting in
preservation of oxytocin synthesis.
In our small group of 34 CP patients, we were indeed able
to detect a negative correlation between BMI and changes in
oxytocin levels before and after breakfast. This ﬁnding links
oxytocin to the main problem of CP survivors with HI,
which is severe hypothalamic obesity and its consequent
long-term negative impact on quality of life [1]. It is already
well established that the hypothalamus is the regulatory
center for feeding and satiety [26]. Oxytocin has also been
linked to energy homeostasis mechanisms in animals, where
it acts as a strong inhibitor of food intake and affects energy
expenditure and glucose homeostasis [27–31]. Oxytocin
Endocrine (2016) 54:524–531 527
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has also been shown to play an important role in metabo-
lism and energy balance in humans [32, 33], such as
reducing caloric intake with a preferential effect on fat
intake [11] and reward-driven food intake in humans [34].
These ﬁndings are in line with our ﬁnding that reduced
levels of delta oxytocin correlate with a high BMI in CP













































Fig. 1 Oxytocin saliva concentrations (pg/ml) in childhood-onset
craniopharyngioma (CP) patients recruited in HIT Endo and
KRANIOPHARYNGEOM 2000/2007 before breakfast (a) and 60
min after standardized breakfast (b) and Δ oxytocin saliva
concentrations (oxytocin concentration after standardized breakfast
vs. oxytocin concentration before breakfast) (c) in CP patients with and
without preoperative hypothalamic involvement (HI) and healthy
controls. The horizontal line in the middle of the box depicts the
median. The top and bottom edges of the box, respectively, mark the
25th and 75th percentiles. Whiskers indicate the range of values that








































Grade 0 Grade 1 Grade 2 Grade 0 Grade 1 Grade 2 Grade 0 Grade 1 Grade 2
Kruskal−Wallis: p = 0.017
Grade 0 vs. grade 1: p = 0.025
Grade 0 vs. grade 2: p = 1
Grade 1 vs. grade 2: p = 0.031
Kruskal−Wallis: p = 0.28 Kruskal−Wallis:
p = 0.51
a)
Fig. 2 Oxytocin saliva concentrations (pg/ml) in childhood-onset
craniopharyngioma (CP) patients recruited in HIT Endo and
KRANIOPHARYNGEOM 2000/2007 before breakfast (a) and 60
min after standardized breakfast (b) and Δ oxytocin saliva
concentrations (oxytocin concentration after standardized breakfast
vs. oxytocin concentration before breakfast) (c) in CP patients with
different grades (grade 0–2) of surgical hypothalamic lesions according
to the grading system of Müller et al. [18, 19]. Grade 0 no
hypothalamic lesions; grade 1 surgical lesions involving anterior
hypothalamic areas, sparing the mammillary bodies; grade 2 surgical
lesions involving anterior and posterior hypothalamic areas involving
the mammillary bodies. The horizontal line in the middle of the box
depicts the median. The top and bottom edges of the box, respectively,
mark the 25th and 75th percentiles. Whiskers indicate the range of




































































Fig. 3 Expression of Δ oxytocin saliva concentrations (oxytocin
concentration after standardized breakfast vs. oxytocin concentration
before breakfast; pg/ml) in craniopharyngioma patients recruited in
HIT Endo and KRANIOPHARYNGEOM 2000/2007 with and without
irradiation therapy (a) with and without diabetes insipidus (b) and
regarding gender (c). The horizontal line in the middle of the box
depicts the median. The top and bottom edges of the box, respectively,
mark the 25th and 75th percentiles. Whiskers indicate the range of
values that fall within 1.5 box-lengths
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patients. We could not demonstrate this delta oxytocin/BMI
correlation in the healthy control group, which might be
explained by the lower variability of BMI. In a recent study
with newly diagnosed type 2 diabetic patients, serum oxy-
tocin levels were lower compared to the control group with
normal glucose tolerance. Serum oxytocin levels were
negatively correlated with BMI, waist circumference, and
other parameters of pathological insulin metabolism [35].
This correlation of low oxytocin levels and a high BMI in
diabetes type 2 patients [35], or minor changes of oxytocin
saliva concentrations in reaction to nutrition (in this study, a
standardized breakfast) and a high BMI, might indicate that
oxytocin is a potential pharmaceutical agent for obesity
treatment. Indeed, this has been tried in patients with
Prader–Willi syndrome (PWS), a genetic disease with
hypothalamic dysfunction, severe obesity, and hyperphagia
as well as cognitive and behavioral problems. Oxytocin
supplementation has been tested in a randomized placebo-
controlled trial in 24 PWS patients [16]. After a single
intranasal administration of oxytocin, improved patients’
trust in others as well as decreased tendencies towards
depressed moods could be observed. Not surprisingly, no
effects on obesity could be detected from this single oxy-
tocin administration [16]. This study demonstrates that
oxytocin therapy might be an option for diseases with
hypothalamic dysfunction-induced behavioral disturbances
and obesity. This therapeutic potential is further reinforced
by a recent case study about a parent having observed
neurobehavioral and pro-social improvement with oxytocin
therapy following surgical resection of their child’s CP [36],
supporting earlier reports on oxytocin effects on social
cognition and afﬁliative behaviour [13–15].
There is a signiﬁcant amount of extant literature per-
taining to the role that oxytocin plays in brain function, and
that one of the major mechanisms associated with oxytocin
is inhibition of the amygdala, reducing feelings of fear and
anxiety [37]. Other studies have found that intranasal oxy-
tocin may activate reward pathways in the globus pallidus,
the striatum, middle frontal gyrus, medial prefrontal cortex,
right orbitofrontal cortex, and the left superior temporal
sulcus in autistic children [38]. However, in order to
recommend intranasal application of oxytocin as a general
therapeutic option for CP-induced hypothalamic dysfunc-
tion, further research is needed regarding the role oxytocin
plays in human metabolism and behavioural functionality.
Limitations of our study are related to the small size of
our cohort and difﬁculties of oxytocin measurement. First, it
remains a matter of discussion whether peripherally mea-
sured oxytocin is indicative for central release patterns and
activities within the brain [39]. Some studies suggest that
certain stimuli lead to coordinated release of central and
peripheral oxytocin, whereas other studies indicate that
certain stimuli change central levels while leaving periph-
eral levels unchanged [40]. In addition, the reliability of
oxytocin measurement is still under debate [39], and issues
have been raised regarding the importance of preanalytical
procedures [41]. In this study, we used saliva samples
measured with EIA after extraction. To avoid analytical
inconsistencies, we measured healthy volunteers as con-
trols, also participating at the 17th Annual Craniophar-
yngioma Meeting, 2014, under the same nutrition
conditions as the CP patients and analyzed all saliva sam-
ples using identical laboratory procedures. We were not
able to analyze other metabolic parameters such as glucose,
lipid and insulin levels and their association with pre- and
post-prandial oxytocin concentrations in saliva. Based on
the results of this pilot study, further investigations
including analyses of these parameters are part of an
upcoming new study in the context of the German Cra-
niopharyngioma Registry.
We conclude that CP patients are able to produce and
secrete the hormone oxytocin, even when pituitary and
hypothalamic structures are damaged. However, patients
with hypothalamic damage grade 1, which involves damage
only to the anterior hypothalamic areas, present with a
signiﬁcant lower fasting level of oxytocin. In addition,
changes in oxytocin levels (Δ oxytocin) before and after
standardized breakfast correlate signiﬁcantly (p= 0.02) with
BMI in CP patients, demonstrating that patients with
hypothalamic obesity show less variation in oxytocin
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Fig. 4 Correlation of Δ oxytocin saliva concentrations (oxytocin
concentration 60 min after standardized breakfast vs. oxytocin con-
centration before breakfast; pg/ml) with body mass index (BMI) SDS
in childhood-onset craniopharyngioma patients (black dots) recruited
in HIT Endo and KRANIOPHARYNGEOM 2000/2007 and controls
(grey dots). r= Pearson correlation coefﬁcient
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supplementation might be a therapeutic optionin CP
patients with hypothalamic obesity and/or neurobehavioral
deﬁcits due to speciﬁc hypothalamic damage in the anterior
hypothalamic area.
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